PMID- 24434342
OWN - NLM
STAT- MEDLINE
DCOM- 20140708
LR  - 20140117
IS  - 1827-1898 (Electronic)
IS  - 0031-0808 (Linking)
VI  - 55
IP  - 4
DP  - 2013 Dec
TI  - The optimal treatment of STEMI: new pharmacological and device approaches.
PG  - 339-43
AB  - Cardiovascular disease remains the leading cause of mortality worldwide. Many 
      deaths are contributed to acute ST elevation myocardial infarction (STEMI). 
      Recently, epidemiological studies have been shown reduction in STEMI related 
      mortality over the last decade. This reduction has partially been attributed to 
      new pharmacological and device advances that were utilized during STEMI 
      treatment. The goal of this manuscript is to review new pharmacological and 
      device approaches available in the treatment of STEMI patients.
FAU - Movahed, M R
AU  - Movahed MR
AD  - CareMore Health Care Arizona, Division of Cardiology The Southern Arizona VA 
      health Care System Tucson, Arizona and Division of Cardiology University of 
      Arizona, Tucson, AZ, USA - rmova@aol.com.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Italy
TA  - Panminerva Med
JT  - Panminerva medica
JID - 0421110
RN  - 0 (Cardiovascular Agents)
SB  - IM
MH  - Absorbable Implants
MH  - *Cardiac Catheters/trends
MH  - Cardiovascular Agents/adverse effects/*therapeutic use
MH  - *Diffusion of Innovation
MH  - Drug-Eluting Stents
MH  - Humans
MH  - Myocardial Infarction/diagnosis/mortality/*therapy
MH  - Percutaneous Coronary Intervention/adverse 
      effects/*instrumentation/mortality/trends
MH  - Prosthesis Design
MH  - *Stents/trends
MH  - Thrombectomy/adverse effects/*instrumentation/mortality/trends
MH  - Treatment Outcome
EDAT- 2014/01/18 06:00
MHDA- 2014/07/09 06:00
CRDT- 2014/01/18 06:00
PHST- 2014/01/18 06:00 [entrez]
PHST- 2014/01/18 06:00 [pubmed]
PHST- 2014/07/09 06:00 [medline]
AID - R41Y2013N04A0339 [pii]
PST - ppublish
SO  - Panminerva Med. 2013 Dec;55(4):339-43.